Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x100px
Organisation › Details

Achilles Therapeutics (Group)

Achilles Therapeutics is a clinical stage, biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase 1/2a trials, the THETIS trial in patients with recurrent or metastatic malignant melanoma and the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC). Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens. Achilles was founded in 2016 by lead investor Syncona Ltd and is supported by an international syndicate of life science investors including RA Capital, Forbion, Invus, Perceptive Advisors, Redmile Group, OrbiMed and Boxer Capital of Tavistock Group. *

 

Period Start 2016-10-03 renamed
  Today Achilles Therapeutics Ltd.
  Predecessor Achilles TX Ltd.
Products Industry T cell therapy
  Industry 2 cancer drug
Person Person Ali, Iraj (Achilles Therapeutics 201812– CEO before Interim CEO + Syncona + McKinsey)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 245 Hammersmith Road
  City W6 8PW London
  Tel +44-20-8154-4600
    Address record changed: 2024-09-28
     
Basic data Employees D: 101 to 500 (2023-12-31)
  Currency USD
  Annual sales 6,081,000 (income, other, total, consolidated (2023) 2023-12-31)
  Profit -69,665,000 (2023-12-31)
  Cash 131,539,000 (2023-12-31)
     
    * Document for »About Section«: Achilles Therapeutics Ltd.. (11/19/20). "Press Release: Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours". Stevenage.
     
   
Record changed: 2024-09-28

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Achilles Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px




» top